JAZ mediates G1 cell-cycle arrest and apoptosis by positively regulating p53 transcriptional activity

Blood

Volumn 108, Issue 13, 2006, Pages 4136-4145

  Yang, Mingli ^a   Wu, Song ^a   Su, Xuekun ^a   May, W Stratford ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; INTERLEUKIN 3; PROTEIN BAX; PROTEIN JAZ; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; ZINC FINGER PROTEIN; BAX PROTEIN, MOUSE; DNA BINDING PROTEIN; P21 ACTIVATED KINASE; PROTEIN SERINE THREONINE KINASE; RNA BINDING PROTEIN; ZFP346 PROTEIN, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CHEMICAL ANALYSIS; CONTROLLED STUDY; DEPHOSPHORYLATION; HEMATOPOIETIC CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; UPREGULATION; ACTIVE TRANSPORT; ANIMAL; BIOSYNTHESIS; CELL NUCLEUS; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; METABOLISM; MOUSE; PROTEIN BINDING; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN A; DNA-BINDING PROTEINS; G1 PHASE; HEMATOPOIETIC STEM CELLS; INTERLEUKIN-3; MICE; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33845505242     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-029645     Document Type: Article

References (72)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
2. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49-58.
3. Ahn J, Prives C. The C-terminus of p53: the more you learn the less you know. Nat Struct Biol. 2001;8:730-732.
4. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22:9030-9040.
5. Jimenez GS, Nister M, Stommel JM, Beeche M, et al. A transactivation- deficient mouse model provides insights into Trp53 regulation and function. Nat Genet. 2000;26:37-43.
6. Slee EA, O'Connor DJ, Lu X. To die or not to die: how does p53 decide? Oncogene. 2004;23:2809-2818.
7. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptotic role at the mitochondria. Mol Cell. 2003;11:577-590.
8. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010-1014.
9. Deng X, Cao F, Flagg T, Anderson J, May WS. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol. 2006;26:4421-4434.
10. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594-604.
11. Ritchie A, Broxmeyer HE. Suppression of p53-mediated growth factor withdrawal-induced apoptosis in the myeloid compartment by hematopoietic cytokines: an overview of hematopoiesis and apoptosis with a presentation of thrombopoietin and the M07E cell line as a model system. Crit Rev Oncol Hematol. 1999;31:169-191.
12. Yonish-Rouach E, Resnitzky D, Lotem J. et al. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature. 1991;35:345-347.
13. Canman CE, Gilmer TM, Coutts SB, et al. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 1995;9:600-611.
14. Blandino G, Scardigli R, Rizzo MG, et al. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene. 1995;10:731-737.
15. Prisco M, Hongo A, Rizzo MG, et al. The insulinlike growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cell Biol. 1997;17:1084-1092.
16. Gottlieb E, Oren M. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J. 1998;17:3587-3596.
17. Vousden KH. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta. 2002;1602:47-59.
18. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899-2908.
19. Sherr CJ. The INK4a/ARF network in tumor suppression. Nat Rev Mol Cell Biol. 2001;2:731-737.
20. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001;8:781-794.
21. Hofmann TG, Moller A, Sirma H, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol. 2002;4:1-10.
22. Jayaraman L, Moorthy NC, Mutthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 1998;12:462-472.
23. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 2003;3:577-587.
24. Dond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005;5:3-8.
25. Banerjee S, Kumar BRP, Kundu TK. General transcriptional coactivator PC4 activates p53 function. Mol Cell Biol. 2004;24:2052-2062.
26. Zheng H, You H, Zhou XZ, et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature. 2002;419:849-853.
27. Fogal V, Gostissa M, Sandy P, et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 2000;19:6185-6195.
28. Gaiddon C, Moorthy NC, Prives C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J. 1999;18:5609-5621.
29. Lu H, Levine AJ. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A. 1995;92:5154-5158.
30. Sui G, Affar el B, Shi Y, et al. Yin Yang 1 is a negative regulator of p53. Cell. 2004;117:859-872.
31. Bai L, Merchant JL. ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol. 2001;21:4670-4683.
32. Yang M, May WS, Ito T. JAZ requires the double-stranded RNA-binding zinc finger motifs for nuclear localization. J Biol Chem. 1999;274:27399-27406.
33. Klug A, Rhodes D. 'Zinc fingers': a novel protein motif for nucleic acid recognition. Trends Biochem Sci. 1987;12:464-469.
34. St Johnston D, Brown NH, Gall JG, Jantsch M. A conserved double-stranded RNA-binding domain. Proc Natl Acad Sci U S A. 1992;89:10979-10983.
35. Draper DE. Protein-RNA recognition. Annu Rev Biochem. 1995;64:593-620.
36. Ito T, Jagus R, May WS. Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A. 1994;91:7455-7459.
37. Nicholson AW. Structure, reactivity, and biology of double-stranded RNA. Prog Nucleic Acid Res Mol Biol. 1996;52:1-65.
38. Ito T, Yang M, May WS. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem. 1999;274:15427-15432.
39. Patel RC, Sen GC. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 1998;17:4379-4390.
40. Chen T, Brownawell AM, Macara IG. Nucleocytoplasmic shuttling of JAZ, a new cargo protein for exportin-5. Mol Cell Biol. 2004;24:6608-6619.
41. Israeli D, Tessler E, Haupt Y, et al. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J. 1997;16:4384-4392.
42. Varneh-Ziaie S, Okan I, Wang Y, et al. Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene. 1997;15:2699-2704.
43. Mendez-Vidal C, Wilhelm MT, Hellborg F, Qian W, Wiman KG. The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity. Nucleic Acids Res. 2002;30:1991-1996.
44. Finerty PJ, Bass BL. A xenopus zinc finger protein that specifically binds dsRNA and RNA-DNA hybrids. J Mol Biol. 1997;271:195-208.
45. Möller HM, Martinez-Yanout MA, Dyson HJ, Wright PE. Solution structure of the N-terminal zinc fingers of the Xenopus laevis double-stranded RNA-binding protein Zfa. J Mol Biol. 2005;351:718-730.
46. Higashi Y, Asanuma M, Miyazaki I, et al. The p53-activated gene, PAG608, requires a zinc finger domain for nuclear localization and oxidative stress-induced apoptosis. J Biol Chem. 2002;277:42224-42232.
47. Hellborg F, Wang Q, Mendez-Vidal C, et al. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene. 2001;20:5466-5474.
48. Yuan XM, Li W, Dalen H, et al. Lysosomal destabilization in p53-induced apoptosis. Proc Natl Acad Sci U S A. 2002;99:6286-6291.
49. Cao X, Deng X, May WS. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood. 2003;102:2605-2614.
50. Schmid I, Sakamoto KM. Analysis of DNA content and green fluorescent protein expression. In: Robinson JP, Darzynkiewicz Z, Dean P, Orfao A, Rabinovitch P, Stewart C, Tanke H, Wheeless L, eds. Current Protocols in Cytometry. New York, NY: John Wiley & Sons; 2001:7.16.1-7.16.10.
51. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
52. Pierani A, Pouponnot C, Calothy G. Transcriptional downregulation of the retina-specific QR1 gene pp60v-src and identification of a novel v-src-responsible unit. Mol Cell Biol. 2004;13:3401-3414.
53. Bennett RL, Blalock WL, Abtahi DM, Pan Y, Moyer SA, May WS. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy and viral infection. Blood. 2006;108:821-829.
54. May WS. Control of apoptosis by cytokines. Adv Pharmacol. 1997;41:219-246.
55. Johnson DE. Regulation of survival pathways by IL-3 and induction of apoptosis following IL-3 withdrawal. Front Biosci. 1998;3:d313-d324.
56. Ali SH, DeCaprio JA. Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin Cancer Biol. 2001;11:15-22.
57. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell. 1992;71:875-886.
58. Selivanova G, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med. 1997;3:632-638.
59. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.
60. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10:699-703.
61. DeCaprio JA, Ludlow JW, Lynch D, et al. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell. 1989;58:1085-1095.
62. Kurokawa K, Tanaka T, Kato J. p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts. Oncogene. 1999;18:2718-2727.
63. Modeston M, Puig-Antich V, Korgaonkar C, Eapen A, Quelle DE. The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. Cancer Res. 2001;61:3145-3150.
64. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727-730.
65. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53. Cell. 1998;92:725-734.
66. Pomerantz J, Schreiber-Agus N, Liégeois NJ, et al. The Ink4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92:713-723.
67. Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004;23:2402-2412.
68. Peters GA, Hartmann R, Qin J, Sen GC. Modular structure of PACT: distinct domains for binding and activating PKR. Mol Cell Biol. 2001;21:1908-1920.
69. Woo RA, Jack MT, Xu Y, Burma S, Chen DJ, Lee PW. DNA-damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J. 2002;21:3000-3008.
70. Jack MT, Woo RA, Hirao A, Cheung A, Mak TW, Lee PW. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci U S A. 2002;99:9825-9829.
71. Jack MT, Woo RA, Motoyama N, Takai H, Lee PW. DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage. J Biol Chem. 2004;279:15269-15273.
72. Stühmer T, Chatterjee M, Hildebrandt M, et al. Nongentoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2006;106:3610-3617.